What Does the Street Think About BioMarin Pharmaceutical Inc. (BMRN)?

Company Overview - BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) develops and commercializes therapies for serious and life-threatening medical conditions and rare diseases, with a product pipeline that includes Valoctocogene roxaparvovec, Vosoritide, and BMN 307 [4] Analyst Ratings and Price Targets - Piper Sandler revised the price target on BioMarin to $84 from $122 on February 6, maintaining an Overweight rating [1] - Barclays initiated coverage of BioMarin with an Overweight rating and an $80 price target on January 27, expressing optimism for the biotech industry in 2026 due to anticipated "significant tailwinds" [2] - Canaccord Genuity upgraded BioMarin to Buy from Hold on January 20, adjusting the price target from $98 to $84, citing the pending acquisition of Amicus as a key catalyst for share price movement [3]